Metabolic alterations caused by HNF1ß expression in ovarian clear cell carcinoma contribute to cell survival

Oncotarget

Volumn 6, Issue 28, 2015, Pages 26002-26017

  Amano, Yasuaki ^a   Mandai, Masaki ^a,b   Yamaguchi, Ken ^a   Matsumura, Noriomi ^a   Kharma, Budiman ^a   Baba, Tsukasa ^a   Abiko, Kaoru ^a   Hamanishi, Junzo ^a   Yoshioka, Yumiko ^a   Konishi, Ikuo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aerobic glycolysis; HNF1 ; Metabolome analysis; Ovarian clear cell carcinoma; ROS

Indexed keywords

AMINO ACID TRANSPORTER; GLUCOSE; GLUTATHIONE; HEPATOCYTE NUCLEAR FACTOR 1BETA; PROTEIN RBAT; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CISPLATIN; GLUTATHIONE DISULFIDE; SLC3A1 PROTEIN, HUMAN;

ARTICLE; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPOXIA; METABOLIC ALTERATION; METABOLISM; MICROARRAY ANALYSIS; OVARY CARCINOMA; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADENOCARCINOMA; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLOME; METABOLOMICS; OVARY TUMOR; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; AMINO ACID TRANSPORT SYSTEMS, BASIC; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLYCOLYSIS; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; METABOLOME; METABOLOMICS; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 84944463959     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4692     Document Type: Article

References (57)

1. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000; Jun 1;88:2584-9.
2. Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, Knapp RC. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989; Jan 32:65-71.
3. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE, Fuller AF Jr. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996; Mar 60:412-7.
4. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012; Sep 126:481-90.
5. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology. 2001; Feb 38:87-95.
6. Giudice LC, Kao LC. Endometriosis. Lancet. 2004; Nov 13-19;364:1789-99.
7. Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol. 2004; Apr 18:349-71.
8. Mandai M, Yamaguchi K, Matsumura N, Baba T, Konishi I. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol. 2009; Oct 14:383-91.
9. Kobayashi H, Sumimoto K, Kitanaka T, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S, Terao T. Ovarian endometrioma-risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol. 2008; Jun 138:187-93. Epub 2007 Dec 26.
10. Mostoufizadeh M, Scully RE. Malignant tumors arising in endometriosis. Clin Obstet Gynecol. 1980; Sep 23:951-63.
11. Yamaguchi K, Mandai M, Toyokuni S, Hamanishi J, Higuchi T, Takakura K, Fujii S. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res. 2008; Jan 1;14:32-40.
12. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010; May 11;107:8788-93.
13. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998; Aug 28;281:1309-12.
14. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009; Jan 1;417:1-13. doi: 10. 1042/BJ20081386.
15. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; Jan 7:11-20.
16. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; Feb 11:85-95.
17. Kobayashi CI, Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. J Cell Physiol. 2012; Feb 227:421-30.
18. Nagano O, Okazaki S, Saya H. Redox regulation in stemlike cancer cells by CD44 variant isoforms. Oncogene. 2013; Oct 31;32:5191-8.
19. Matsumura N, Mandai M, Okamoto T, Yamaguchi K, Yamamura S, Oura T, Baba T, Hamanishi J, Kang HS, Matsui S, Mori S, Murphy SK, Konishi I. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci. 2010; Dec 101:2658-63.
20. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, Matsui S, Murphy SK, Konishi I. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene. 2010; Mar 25;29:1741-52.
21. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, Lindner T, Yamagata K, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Iwamoto Y, Bell GI. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet. 1997; Dec 17:384-5.
22. D'Angelo A, Bluteau O, Garcia-Gonzalez MA, Gresh L, Doyen A, Garbay S, Robine S, Pontoglio M. Hepatocyte nuclear factor 1alpha and beta control terminal differentiation and cell fate commitment in the gut epithelium. Development. 2010; May 137:1573-82.
23. Jin L, Kikuchi R, Saji T, Kusuhara H, Sugiyama Y. Regulation of tissue-specific expression of renal organic anion transporters by hepatocyte nuclear factor 1 a/ß and DNA methylation. J Pharmacol Exp Ther. 2012; Mar 340:648-55.
24. Kornfeld JW, Baitzel C, Könner AC, Nicholls HT, Vogt MC, Herrmanns K, Scheja L, Haumaitre C, Wolf AM, Knippschild U, Seibler J, Cereghini S, Heeren J, Stoffel M, Brüning JC. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature. 2013; Feb 7;494:111-5.
25. Okamoto T, Mandai M, Matsumura N, Yamaguchi K, Kondoh H, Amano Y, Baba T, Hamanishi J, Abiko K, Kosaka K, Murphy SK, Mori S, Konishi I. Hepatocyte nuclear factor-1ß (HNF-1ß) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Mol Carcinog. 2015; Jan 54:35-49.
26. Warburg O. On the origin of cancer cells. Science. 1956; Feb 24;123:309-14.
27. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008; Sep 5;134:703-7.
28. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; May 22;324:1029-33.
29. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011; May 11:325-37.
30. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007; Apr 11:321-33.
31. Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, Gillies RJ. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia. 2008; Aug 10:745-56.
32. Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem. 2011; Dec 9;286:42626-34.
33. Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M. The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res. 2008; Jul 1;68:5198-205.
34. Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J, Konishi I. Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett. 2011; Nov 28;310:129-33.
35. Semenza GL. Tumor metabolism: cancer cells give and take lactate. J Clin Invest. 2008; Dec 118:3835-7.
36. Pértega-Gomes N, Vizcaíno JR, Attig J, Jurmeister S, Lopes C, Baltazar F. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer. 2014; May 21;14:352.
37. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013; Mar 7;4:e532.
38. Dang CV. PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect. Sci Signal. 2009; Nov 17;2:pe75.
39. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci. 1999; Feb 24:68-72.
40. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003; Oct 15;552:335-44.
41. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/ glutathione couple. Free Radic Biol Med. 2001; Jun 1;30:1191-212.
42. Bannai S, Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals. J Membr Biol. 1986; 89:1-8.
43. Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med. 1999; Nov 27:916-21.
44. Venè R, Castellani P, Delfino L, Lucibello M, Ciriolo MR, Rubartelli A. The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets. Antioxid Redox Signal. 2011; Nov 1;15:2439-53.
45. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012; Feb 19;14:276-86.
46. Sauert K, Kahnert S, Roose M, Gull M, Brändli AW, Ryffel GU, Waldner C. Heat-shock mediated overexpression of HNF1ß mutations has differential effects on gene expression in the Xenopus pronephric kidney. PLoS One. 2012; 7:e33522.
47. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013; Nov 12:829-46.
48. Vaughan RA, Garcia-Smith R, Dorsey J, Griffith JK, Bisoffi M, Trujillo KA. Tumor necrosis factor alpha induces Warburg-like metabolism and is reversed by anti-inflammatory curcumin in breast epithelial cells. Int J Cancer. 2013; Nov 15;133:2504-10.
49. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res. 2010; Feb 1;70:859-62.
50. Dang CV. Links between metabolism and cancer. Genes Dev. 2012; May 1;26:877-90.
51. Kornfeld JW, Baitzel C, Könner AC, Nicholls HT, Vogt MC, Herrmanns K, Scheja L, Haumaitre C, Wolf AM, Knippschild U, Seibler J, Cereghini S, Heeren J, Stoffel M, Brüning JC. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature. 2013; Feb 7;494:111-5.
52. Versantvoort CH, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman PR. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer. 1995; Jul 72:82-9.
53. Huang Y, Dai Z, Barbacioru C, Sadée W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005; Aug 15;65:7446-54.
54. Soga T, Heiger DN. Amino acid analysis by capillary electrophoresis electrospray ionization mass spectrometry. Anal Chem. 2000; Mar 15;72:1236-41.
55. Ishii N, Nakahigashi K, Baba T, Robert M, Soga T, Kanai A, Hirasawa T, Naba M, Hirai K, Hoque A, Ho PY, Kakazu Y, Sugawara K, et al. Multiple high-throughput analyses monitor the response of E. coli to perturbations. Science. 2007; Apr 27;316:593-7.
56. Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, Yamaguchi K, Murakami R, Yamamoto A, Kharma B, Kosaka K, Konishi I. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res. 2013; Mar 15;19:1363-74.
57. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; Apr 4:249-64.